Until's Cryopreservation: Decoupling Biology From Medical Timelines

The Unseen Horizon: How Until's Cryopreservation Aims to Redefine Medical Timelines

This conversation with Laura Deming, CEO of Until, delves into a seemingly futuristic concept: reversible cryopreservation. Beyond the science fiction allure, the core implication is profound: the potential to decouple biological time from medical necessity. The immediate benefit isn't just about freezing things; it's about creating a temporal buffer, a "future ambulance," for critical medical interventions. This exploration is crucial for anyone involved in biotech, medicine, or long-term technological vision, offering a glimpse into how fundamental scientific challenges can be reframed and tackled, potentially unlocking immense value by making time itself a malleable variable. The hidden consequences lie not just in the technical hurdles, but in how this capability could reshape our understanding of disease progression, organ transplantation, and even the very concept of life's finite timeline.

The Temporal Paradox: When Time is the Enemy, Not the Disease

The most striking revelation from this discussion is the framing of time not as a constant, but as a critical, often insurmountable, obstacle in medicine. Laura Deming articulates a vision where cryopreservation acts as an "ambulance to the future," a mechanism to pause biological processes until a cure or treatment becomes available. This isn't just about extending life; it's about bridging the gap between a patient's immediate need and the discovery of life-saving therapies. The stark reality is highlighted by the anecdote of a co-founder's father-in-law who missed a critical clinical trial by mere months due to the inexorable march of time. This underscores a fundamental systemic flaw: our current medical system is often outpaced by scientific advancement, leaving patients with terminal illnesses vulnerable not just to their disease, but to the calendar.

The scientific challenge, as Deming explains, is elegantly simple yet devilishly complex: ice formation. "Water expands when it forms ice," she states, "and that's just hard for your tissue to take without substantial damage." The core problem is that ice crystals rupture cell membranes. However, the breakthrough lies in understanding that ice formation is not an instantaneous event but a probabilistic process. By carefully modulating nucleation and extension rates, and by minimizing time spent in the critical temperature range where ice can form, it becomes possible to traverse to sub-zero temperatures without significant ice damage. This probabilistic approach is key; it shifts the problem from an absolute barrier to a manageable engineering and biological challenge.

"The main question is not is this possible to do at all, it's is it possible to scale up."

-- Laura Deming

This quote encapsulates the central thesis of Until's work. The existence of cryopreserved human embryos, viable for decades, proves the fundamental possibility. The challenge, then, becomes scaling this capability from a few hundred cells to complex, vascularized organs, and eventually, to the entire human body. This scaling introduces a cascade of downstream effects. For organ transplantation, time is currently a ruthless constraint; organs expire quickly after procurement. Until's near-term goal of reversibly cryopreserving single organs aims to eliminate this constraint, allowing for more efficient matching and transportation, and ultimately, saving organs that would otherwise be lost. This directly addresses a "social blindspot" around aging and death, reframing it as a problem solvable through technological intervention.

Engineering the Biological Frontier: The Power of Interdisciplinary Levers

A particularly insightful aspect of the conversation is the explicit embrace of engineering principles to solve biological problems. Deming highlights how much of the work at Until involves engineering challenges--optimizing cooling and rewarming rates--rather than solely biological ones. This is a critical distinction. In many biological fields, progress is slow and incremental. However, by leveraging engineering, it's possible to create tools that modulate biological outcomes. For instance, faster cooling and rewarming rates can reduce the need for high concentrations of cryoprotective agents (CPAs), which are inherently toxic.

"You can trade off like engineering difficulty and biological difficulty to a non zero degree. Not not 100%. Like you you can't just use engineering to solve the problem. You absolutely have biological questions. And like this questions could come out in the negative for some use cases. So that's, not saying you can just make an engineering problem, but like, you can make your life easier on the biology front by building better engineering tooling. And the fact that that's possible is a huge deal. That is that is not true for most problems in biology."

-- Laura Deming

This interdisciplinary approach is where significant competitive advantage can be built. While others might be solely focused on the biological intricacies of tissue survival, Until is simultaneously developing the engineering infrastructure to support and enhance those biological processes. This creates a virtuous cycle: better engineering enables more effective biological experimentation, which in turn informs further engineering development. This is precisely why the field has been historically under-resourced; it requires a rare confluence of biological understanding and engineering prowess, a combination that is difficult to find and fund. The immediate discomfort for engineers is grappling with biological complexities, and for biologists, it's embracing the precision and demands of engineering. But the payoff--the ability to control biological time--is immense.

The Long Game: Patience, Precision, and the Unpopular Path

The pursuit of whole-body reversible cryopreservation is, by its nature, a long-term endeavor. Deming acknowledges that while a clear roadmap is emerging, the timeline for such a monumental achievement remains uncertain, particularly concerning the brain. This presents a leadership challenge: how to maintain urgency and recruit top talent for a goal that may not yield immediate, visible results. The strategy Until employs is to have a concrete, near-term product goal--organ cryopreservation for transplantation--which serves as a crucial benchmark.

"I think the only thing that was inferring just about that product was like, if we're at all talking about whole body reversible cryopreservation and we can't make a dent on that problem, like there's no version of not going through it. Yeah. And so the thing is, where like, if you're serious that should be doable and if like, you can't do that then like you're not the company to like do the long term things."

-- Laura Deming

This approach allows the company to demonstrate technical viability and attract resources, while simultaneously building the foundational technologies for the ultimate goal. It’s a strategy that requires patience from investors and a deep belief in the underlying science from the team. The "social blindspot" around aging and death often leads to a lack of serious investment and research in fields like cryopreservation. By tackling the problem head-on, with a clear scientific rationale and a phased approach, Until is not only pushing the boundaries of science but also challenging conventional wisdom about what is possible and what is worth pursuing. The individuals who thrive in this environment are those who can tolerate ambiguity, embrace difficult problems, and understand that true breakthroughs often require years of meticulous, often unglamorous, work. This is where lasting competitive advantage is forged--in the willingness to undertake the hard, long-term bets that others shy away from.

Key Action Items:

• Immediate Action (Next 6-12 months):
  • Advance Organ Cryopreservation Technology: Focus R&D on improving the efficiency and viability of cryopreserving human organs for transplantation, aiming for preclinical and early clinical studies.
  • Develop Advanced Rewarming Techniques: Invest in engineering solutions for rapid and uniform rewarming of larger biological structures, mitigating thermal damage.
  • Quantify CPA Toxicity Thresholds: Conduct rigorous studies to determine the maximum tolerable concentrations of cryoprotective agents for various tissues and organs.
• Medium-Term Investment (1-3 years):
  • Scale Up to Small Animal Models: Translate successes in organ cryopreservation to whole-body cryopreservation in small animals (e.g., rats) to validate complex systemic challenges.
  • Establish Robust Monitoring and Assessment Protocols: Develop standardized methods for evaluating the long-term viability and functional recovery of cryopreserved tissues and organs.
  • Build Interdisciplinary Talent Pipeline: Actively recruit and foster talent at the intersection of biology, engineering, and materials science, emphasizing problem-solving skills over dogma.
• Long-Term Strategic Investment (3-5+ years):
  • Address Whole-Body Cryopreservation Challenges: Dedicate resources to understanding and overcoming the unique biological hurdles of whole-body cryopreservation, with a specific focus on neural tissue.
  • Explore Ethical and Societal Frameworks: Proactively engage in discussions about the ethical implications and societal impact of advanced cryopreservation technologies to guide responsible development.
  • Seek Strategic Partnerships: Collaborate with academic institutions and other research organizations to accelerate progress and share knowledge in the broader field of cryobiology.